For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These include the rise of small-market pharmaceuticals, increased titers and process productivity, the emergence of biosimilars, the evolution of healthcare reform, greater competition and tighter capital markets.
As manufacturing and facilities managers confront these challenges — and are still tasked with meeting today’s capacity needs — many are turning to a new flexible factory platform that will accelerate their implementation of biomanufacturing capacity while lowering risk, reducing time to market and reducing capital costs.
A new white paper, “The Flexible Factory Concept: A Flexible Bioprocessing Platform to Meet the Changing Needs of Biomanufacturing,”
The white paper defines the “Flexible Factory Concept” as a modular biomanufacturing platform that leverages single-use technology, controlled environment modules and advanced process automation. The paper outlines the strategic advantages and benefits of the flexible factory concept for biomanufacturers, including unequaled gains in speed to market, economics, risk mitigation, and flexibility.
Download the white paper, “The Flexible Factory Concept: A Flexible Bioprocessing Platform to Meet the Changing Needs of Biomanufacturing,”
# # #
Xcellerex is commercializing turnkey biomanufacturing solutions that transform the speed and economics of producing therapeutic proteins, including biosimilars and vaccines. The company’s FlexFactory®